![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1812461
Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å(Trastuzumab Emtansine) ½ÃÀå : ÀûÀÀÁõº°, ³óµµº°, ¿¬·ÉÃþº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åë ä³Îº°, Áö¿ªº°Trastuzumab Emtansine Market, By Indication, By Strength, By Age Group, By End User, By Distribution Channel, By Geography |
Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å(Trastuzumab Emtansine) ½ÃÀåÀº 2025³â¿¡ 25¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 45¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀ̸ç, 2025-2032³â CAGR·Î 8.7%ÀÇ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.
¸®Æ÷Æ® ¹üÀ§ | ¸®Æ÷Æ® »ó¼¼ | ||
---|---|---|---|
±âÁØ¿¬µµ | 2024 | 2025³â ½ÃÀå ±Ô¸ð | 25¾ï 4,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR : | 8.70% | 2032³â °¡Ä¡ ¿¹Ãø | 45¾ï 5,000¸¸ ´Þ·¯ |
HER2 ¾ç¼º À¯¹æ¾ÏÀ» Ä¡·áÇϱâ À§ÇØ ¼³°èµÈ Çõ½ÅÀûÀÎ Ç×ü¾à¹°Á¢ÇÕü(ADC)¿¡ ÃÊÁ¡À» ¸ÂÃá ¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀåÀº ¾Ï Ä¡·áÁ¦ÀÇ Àü¸Á¿¡¼ Áß¿äÇÑ ºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½ÅÀº Æ®¶ó½ºÅõÁÖ¸¿ÀÇ Ç¥Àû ƯÀ̼º°ú ¿¥Åº½ÅÀÇ ¼¼Æ÷µ¶¼º È¿´ÉÀ» °áÇÕÇÏ¿© Àü½Å µ¶¼ºÀ» ÃÖ¼ÒÈÇÏ¸é¼ ¾Ï¼¼Æ÷¿¡ Á÷Á¢ ÈÇпä¹ýÀ» ½ÃÇàÇÏ´Â Á¤¹ÐÀǷḦ ½ÇÇöÇÕ´Ï´Ù. ÀÌ Ä¡·á¹ýÀÇ ¹ßÀüÀº HER2 ¾ç¼º ÀüÀ̼º À¯¹æ¾Ï ȯÀÚ, ƯÈ÷ Æ®¶ó½ºÅõÁÖ¸¿°ú Ź»ê ±â¹Ý Ä¡·á¸¦ ¹ÞÀº ÀûÀÌ Àִ ȯÀÚµéÀÇ Ä¡·á ÆÐ·¯´ÙÀÓ¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù.
ÀÌ ½ÃÀå¿¡´Â Á¦¾à»ç, ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ, ±ÔÁ¦ ´ç±¹, ȯÀÚ Áö¿ø ´Üü µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ Âü¿©Çϰí ÀÖÀ¸¸ç, ÀÌ ¸ðµç ÀÌÇØ°ü°èÀÚµéÀÌ ÀÌ »ý¸íÀ» ±¸ÇÏ´Â Ä¡·á¹ýÀÇ °³¹ß°ú º¸±Þ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÀÇ·á°¡ ¾Ï ºÐ¾ß¿¡¼ °è¼Ó ÁÖ¸ñ¹Þ°í ÀÖ´Â °¡¿îµ¥, Æ®¶ó½ºÅõÁÖ¸¿ ¿¥ÅĽÅÀº º¸´Ù Ç¥ÀûÈµÈ È¿°úÀûÀÎ Ä¡·áÁ¦·ÎÀÇ ÁøÈ¸¦ »ó¡ÇÕ´Ï´Ù. ¼¼°è ½ÃÀå ¿ªÇÐÀº À¯¹æ¾Ï ¹ßº´·ü Áõ°¡, HER2 °Ë»ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë, º´¿ë¿ä¹ý ¹× ÀûÀÀÁõ È®´ë¸¦ À§ÇÑ ÁøÇà ÁßÀÎ Àӻ󿬱¸ µîÀÇ ¿äÀο¡ ¿µÇâÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¿äÀεéÀº ÀÌ ½ÃÀåÀ» ´õ ³ÐÀº ¾Ï Ä¡·áÁ¦ ºÎ¹®¿¡ Áß¿äÇÑ ±â¿©¸¦ ÇÏ´Â ½ÃÀåÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀåÀº ±¹Á¦ ÀÇ·á ½Ã½ºÅÛ Àü¹Ý¿¡ °ÉÃÄ Áö¼ÓÀûÀ¸·Î È®´ëµÇ°í ÀÖ´Â ¸î °¡Áö °·ÂÇÑ ÃËÁø¿äÀο¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ±× ù ¹øÂ° ¿äÀÎÀº Àü ¼¼°è À¯¹æ¾Ï ȯÀÚÀÇ ¾à 20-25%°¡ HER2 ¾ç¼º À¯¹æ¾ÏÀ¸·Î Àü ¼¼°è À¯¹æ¾Ï ȯÀÚÀÇ ¾à 20-25%°¡ HER2 ¾ç¼º À¯¹æ¾Ï¿¡ °É¸®°í ÀÖ½À´Ï´Ù. Áø´Ü ´É·ÂÀÇ Çâ»ó°ú HER2 °Ë»ç ÇÁ·ÎÅäÄÝÀÇ º¸±ÞÀ¸·Î ȯÀÚ ½Äº° ¹× Ä¡·á¹ý ¼±ÅÃÀÌ Å©°Ô °³¼±µÇ¾î ½ÃÀå ¼ºÀå¿¡ Á÷Á¢ÀûÀ¸·Î ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±âÁ¸ ÈÇпä¹ý ´ëºñ Æ®·ç½ºÅõÁÖ¸¿ ¿¥ÅĽÅÀÇ ¿ì¼öÇÑ È¿´É ÇÁ·ÎÆÄÀÏÀº ¹«ÁøÇà »ýÁ¸À²°ú Àüü »ýÁ¸À² °³¼±À» º¸¿©ÁÖ´Â Áß¿äÇÑ ÀÓ»ó½ÃÇèÀ» ÅëÇØ ÀÔÁõµÇ¾î ÀÇ»çµéÀÇ Ã¤Åðú ȯÀÚµé ¼ö¿ä¸¦ Áö¼ÓÀûÀ¸·Î °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
±×·¯³ª ÀÌ ½ÃÀåÀº ³Î¸® ÀÌ¿ëµÇ°í äÅõǴ °ÍÀ» ¹æÇØÇÏ´Â Å« ¾ïÁ¦¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Æ®¶ó½ºÅõÁÖ¸¿ ¿¥ÅĽÅÀÇ Ä¡·áºñ´Â ȯÀÚ 1ÀÎ´ç ¿¬°£ 10¸¸ ´Þ·¯°¡ ³Ñ´Â °í°¡À̸ç, ƯÈ÷ ÀÇ·á ¿¹»êÀÌ ÇÑÁ¤µÈ ½ÅÈï ±¹°¡¿¡¼´Â ÀÇ·á ½Ã½ºÅÛ, º¸Çè ÇÁ·Î¹ÙÀÌ´õ, ȯÀڵ鿡°Ô Å« °æÁ¦Àû À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ±î´Ù·Î¿î ½ÂÀÎ °úÁ¤°ú º¹ÀâÇÑ Á¦Á¶ ¿ä°ÇÀº ½ÃÀå ÁøÀÔ À庮°ú °ø±Þ¸Á¿¡ ´ëÇÑ µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç÷¼ÒÆÇ °¨¼Ò, °£µ¶¼º, ½ÉÀå ±â´É Àå¾Ö¿Í °°Àº ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀº ȯÀÚÀÇ ½ÅÁßÇÑ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇϸç, Ä¡·á ÀÚ°ÝÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí ÀüÀ̼º À¯¹æ¾Ï ¿Ü¿¡µµ ¼ö¼ú ÈÄ º¸Á¶¿ä¹ý, À§¾Ï µî HER2 ¾ç¼º ¾Ç¼º Á¾¾ç¿¡ ´ëÇÑ ÀûÀÀÁõÀÌ È®´ëµÇ¸é¼ Å« ºñÁî´Ï½º ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ßÀº ºñ¿ë Àý°¨°ú ½ÃÀå Á¢±Ù¼º È®´ëÀÇ ±âȸ°¡ ÀÖÀ¸¸ç, ¸é¿ª¿ä¹ý ¹× ´Ù¸¥ Ç¥ÀûÄ¡·áÁ¦¿ÍÀÇ º´¿ë¿ä¹ý Àü·«Àº Ä¡·á ¼º°ú Çâ»ó°ú ´Ù¾çÇÑ È¯ÀÚ±º¿¡¼ ½ÃÀå È®´ë °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
Trastuzumab Emtansine Market is estimated to be valued at USD 2.54 Bn in 2025 and is expected to reach USD 4.55 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 2.54 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 8.70% | 2032 Value Projection: | USD 4.55 Bn |
The global trastuzumab emtansine market represents a critical segment within the oncology therapeutics landscape, focusing on an innovative antibody-drug conjugate (ADC) designed to treat HER2-positive breast cancer. Trastuzumab emtansine combines the targeted specificity of trastuzumab with the cytotoxic potency of emtansine, creating a precision medicine approach that delivers chemotherapy directly to cancer cells while minimizing systemic toxicity. This therapeutic advancement has revolutionized treatment paradigms for patients with HER2-positive metastatic breast cancer, particularly those who have previously received trastuzumab and taxane-based therapies.
The market encompasses various stakeholders including pharmaceutical manufacturers, healthcare providers, regulatory bodies, and patient advocacy groups, all contributing to the development and accessibility of this life-saving treatment. As personalized medicine continues to gain prominence in oncology, trastuzumab emtansine exemplifies the evolution toward more targeted, effective therapeutic interventions. The global market dynamics are influenced by factors such as increasing breast cancer incidence rates, growing awareness of HER2 testing, expanding healthcare infrastructure in emerging markets, and ongoing clinical research exploring combination therapies and expanded indications, positioning this market as a significant contributor to the broader oncology pharmaceutical sector.
The global trastuzumab emtansine market is propelled by several robust drivers that continue to fuel its expansion across international healthcare systems. The primary driver remains the increasing global incidence of HER2-positive breast cancer, affecting approximately 20-25% of all breast cancer patients worldwide, creating a substantial patient population requiring targeted therapeutic interventions. Enhanced diagnostic capabilities and widespread implementation of HER2 testing protocols have significantly improved patient identification and treatment selection, directly contributing to market growth. The superior efficacy profile of trastuzumab emtansine compared to conventional chemotherapy regimens, demonstrated through pivotal clinical trials showing improved progression-free survival and overall survival rates, continues to drive physician adoption and patient demand.
However, the market faces considerable restraints that challenge widespread accessibility and adoption. The exceptionally high cost of trastuzumab emtansine treatment, often exceeding US$ 100,000 annually per patient, creates significant financial barriers for healthcare systems, insurance providers, and patients, particularly in developing economies with limited healthcare budgets. Stringent regulatory approval processes and complex manufacturing requirements contribute to market entry barriers and supply chain challenges. Additionally, potential adverse effects including thrombocytopenia, hepatotoxicity, and cardiac dysfunction require careful patient monitoring and may limit treatment eligibility. Despite these challenges, substantial opportunities emerge from expanding indications beyond metastatic breast cancer, including adjuvant settings and other HER2-positive malignancies such as gastric cancer. Biosimilar development presents opportunities for cost reduction and increased market access, while combination therapy strategies with immunotherapies and other targeted agents offer potential for enhanced therapeutic outcomes and market expansion in diverse patient populations.
Key features of the study